Neutron Capture Therapy for Amyloid Beta Destruction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective way to destroy the structure of amyloid β-protein, a key contributor to Alzheimer's disease, which is essential for treating the disease.
Innovation Solution
A neutron capture therapy system utilizing a compound with a nuclide having a large thermal neutron capture cross section, such as 10B, that binds specifically to amyloid β-protein, generating energy from neutron beams to destroy the protein while minimizing damage to normal tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to treat amyloid β-protein, then the treatment approach is simple, but there is no effective way to destroy the protein structure
Solution Approach 1:
The patent introduces a compound containing nuclides (such as 10B, 155Gd, or 157Gd) as an intermediary substance that specifically binds to amyloid β-protein. This compound acts as a mediator between the neutron beam and the target protein, enabling selective destruction of the protein structure through nuclear reactions while sparing surrounding healthy tissue. The compound serves as the crucial link that makes the therapy effective and selective.
Solution Approach 2:
The patent utilizes the parameter of neutron capture cross section, selecting nuclides with exceptionally large thermal neutron capture cross sections (at least 100 times greater than basic human body elements). By changing the nuclear parameter (neutron capture cross section) of the targeted substance, the therapy achieves high efficacy in destroying amyloid β-protein structure while minimizing damage to normal tissues.
2Reliability
If a neutron beam is used to destroy amyloid β-protein, then the protein structure can be effectively destroyed, but normal tissue may be damaged
Solution Approach 1:
The patent applies local quality by making the therapeutic effect highly localized to where the compound binds to amyloid β-protein. The compound accumulates specifically at the site of amyloid deposits, and the neutron capture reaction occurs only at these localized sites. This ensures that the harmful effect (protein destruction) is confined to the pathological area while normal tissues receive minimal or no damage.
Solution Approach 2:
The patent converts the potentially harmful neutron radiation into a beneficial therapeutic tool. By having the compound with high neutron capture cross section nuclides specifically bind to amyloid β-protein, the neutron beam's energy is selectively absorbed and converted into localized destruction of the harmful protein structure, transforming a potentially damaging radiation into a targeted therapeutic agent.
3Reliability
If peptidases like IDE and NEP are used to degrade amyloid β-protein, then the protein can be reduced, but these enzymes are zinc-dependent and may not work in all conditions
Solution Approach 1:
The patent replaces the biochemical mechanism (enzyme-catalyzed degradation requiring zinc ions and specific physiological conditions) with a physical mechanism (neutron capture therapy). Instead of relying on biological enzymes that have specific substrate requirements and cofactor dependencies, the therapy uses physical neutron radiation that can destroy protein structures directly without requiring any biological conditions, thereby achieving universal applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system efficiently targets and reduces amyloid β-protein accumulation, potentially delaying or relieving Alzheimer's disease symptoms with minimal harm to normal tissues.
Implementation Method 1
the compound contains a nuclide with a large thermal neutron capture cross section; and wherein the energy generated by the action of a neutron beam generated by the neutron capture therapy device on the nuclide of the compound destroys the structure of the amyloid β-protein
Data Source
AI summary
A neutron capture therapy system capable of eliminating amyloid β-protein includes a neutron capture therapy device and a compound capable of specifically binding to the amyloid β-protein having a nuclide with a large thermal neutron capture cross section. The neutron capture therapy device includes a neutron source, a beam shaping assembly and a collimator, the neutrons released by the neutron source pass through the beam shaping assembly and are slowed into a neutron beam within a certain energy range. The neutron beam irradiates the compound, and the energy generated by the reaction thereof can destroy the structure of the amyloid β-protein. The neutron capture therapy system can specifically eliminate the amyloid β-protein, and reduce the damage to the tissues surrounding the amyloid β-protein.